^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
autologous 3rd generation CD19-targeting CAR T cell therapy
i
Other names: autologous 3rd generation CD19-targeting CAR T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Uppsala University
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
3years
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy (clinicaltrials.gov)
P2, N=24, Completed, Uppsala University | Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Aug 2021 | Trial primary completion date: Apr 2022 --> Aug 2021
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
autologous 3rd generation CD19-targeting CAR T cell therapy
Share via
